Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence
A Mukund, MA Afridi, A Karolak, MA Park, JB Permuth… - Cancers, 2024 - mdpi.com
Simple Summary Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the deadliest
forms of cancer, characterized by high rates of metastasis, late detection, and poor …
forms of cancer, characterized by high rates of metastasis, late detection, and poor …
Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype
Bulk analyses of pancreatic ductal adenocarcinoma (PDAC) samples are complicated by the
tumor microenvironment (TME), ie signals from fibroblasts, endocrine, exocrine, and immune …
tumor microenvironment (TME), ie signals from fibroblasts, endocrine, exocrine, and immune …
[HTML][HTML] Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy
NK Horvat, I Karpovsky, M Phillips… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor. Prognosis
is poor and survival is low in patients diagnosed with this disease, with a survival rate of …
is poor and survival is low in patients diagnosed with this disease, with a survival rate of …
The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids
The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids:
Cell Stem Cell Skip to Main Content Advertisement Cell Stem Cell This journal offers authors …
Cell Stem Cell Skip to Main Content Advertisement Cell Stem Cell This journal offers authors …
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
JJ Lee, JJ Yeh - Surgical Clinics, 2024 - surgical.theclinics.com
Despite significant research efforts and clinical trials, pancreatic ductal adenocarcinoma
(PDAC) remains a deadly disease and is now projected to become the second leading …
(PDAC) remains a deadly disease and is now projected to become the second leading …
Integration of Molecular, Histological, and Immunological Markers of Clinical Performance in Pancreatic Ductal Adenocarcinoma and Breast Cancer
L Torre-Healy - 2023 - search.proquest.com
Molecular subtyping in tumors has been a staple of oncology research for decades.
However, we spend more time redefining subtypes than we do generating workflows for …
However, we spend more time redefining subtypes than we do generating workflows for …